Drug Profile
Varicella zoster immune globulin - Kamada
Alternative Names: VariZIGLatest Information Update: 19 May 2023
Price :
$50
*
At a glance
- Originator Cangene Corporation
- Developer Saol Therapeutics
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Varicella zoster virus infections
Most Recent Events
- 31 Dec 2022 Varicella zoster immune globulin is available on a Named Patient Access Programme for the treatment of Varicella zoster virus infections (Prevention) in Belgium, Kuwait, Netherlands, Sweden, the United Arab Emirates, Norway, Denmark, and Estonia
- 22 Nov 2021 Kamada acquires Varicella zoster immunoglobulin from Saol Therapeutics
- 28 Sep 2017 Saol Therapeutics completes the acquisition of Varicella zoster immunoglobulin from Aptevo Therapeutics